文献速递血管炎

利妥昔单抗联合甲氨蝶呤作为持续性活动性肉芽肿性多血管炎的挽救治疗

Rituximab plus methotrexate combination as a salvage therapy in persistently active granulomatosis with polyangiitis.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

6个月时88%患者达总体缓解,末次评估时94%缓解;41%发生严重不良事件,24%因感染等事件停药但非因安全性。联合治疗可能是有一定安全性的有效挽救方案。

要点

  • RTX/MTX联合治疗在持续性活动性GPA中6个月总体缓解率88%,末次评估94%。
  • 严重不良事件发生率41%,感染占24%,24%患者停药但非因安全性。
  • 多数患者此前RTX(94%)或CYC(65%)治疗失败,中位 flares 3次。

核心结论

  • RTX/MTX联合治疗可能是治疗持续性活动性GPA伴肉芽肿性表现的有效挽救治疗,且安全性可接受。

研究设计与样本

  • 所有患者均为GPA,76% ANCA阳性,主要为PR3-ANCA特异性。

主要发现

  • 16例(94%)此前RTX未达缓解,11例(65%)此前CYC未达缓解。
  • 患者中位 flares 次数为3次(2-4次)。
  • 6个月时15例(88%)达总体缓解,其中部分缓解11例(65%)、完全缓解4例(24%)。
  • 末次评估时16例(94%)达总体缓解。
  • 7例(41%)发生严重不良事件(3或4级),包括感染4例(24%)和肝炎2例(12%)。

关键数值与推荐

  • RTX/MTX联合治疗中位随访时间为11个月(11-26个月)。
  • 4例(24%)停用联合治疗,但均非因安全性顾虑;2例(12%)因不良事件降低MTX剂量。
  • 1例患者因不明原因死亡。

临床怎么用

  • 对RTX或CYC治疗失败的持续性活动性GPA伴肉芽肿性表现患者,可考虑RTX/MTX联合作为挽救治疗。
  • 治疗期间需监测严重不良事件,尤其是感染和肝炎。

局限性

  • 无对照组,疗效与安全性结论需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to describe the efficacy and safety of rituximab and MTX (RTX/MTX) combination therapy in ANCA-associated vasculitides (AAV). METHODS: A retrospective French nationwide study was conducted in patients with AAV who received RTX/MTX combination therapy for persistently active disease. RESULTS: Seventeen patients were included. All patients had granulomatosis with polyangiitis (GPA), with positive ANCA in 76% of them, mainly with PR3-ANCA specificity. Sixteen patients (94%) had priorly failed to achieve remission with RTX and 11 (65%) with CYC. Patients had experienced a median of 3 (2-4) flares. Manifestations requiring RTX/MTX combination therapy were subglottic or bronchial stenosis in 6 patients (35%), orbital mass in 6 (35%), disabling ENT involvement in 2 (12%), and epiduritis and pachymeningitis in 1 case (6%) each. The median follow-up duration for the RTX/MTX combination therapy was 11 months (11-26 months). At 6 months, global response had been achieved in 15 patients (88%), including partial response in 11 (65%) and complete response in 4 (24%). At last evaluation, global response had been achieved in 16 patients (94%). Seven patients (41%) experienced severe adverse events (grade 3 or 4), including infections in 4 (24%) and hepatitis in 2 (12%). Combination therapy was withdrawn in 4 patients (24%), but never for safety concerns. In contrast, the MTX dose was decreased in 2 patients (12%) because of adverse events. One patient died of an unknown cause. CONCLUSION: RTX/MTX combination therapy could be an effective salvage therapy to treat persistently active GPA with granulomatous manifestations, with an acceptable safety profile.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Sorin B, Samson M, Durel CA, et al. Rituximab plus methotrexate combination as a salvage therapy in persistently active granulomatosis with polyangiitis. Rheumatology (Oxford). 2022. PMID: 34698818. doi:10.1093/rheumatology/keab791

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。